Recent Updates
Recently added Catalysts
ZYME

Celgene Selects Lead Oncology Therapeutic Candidate Under Bispecific Antibody Collaboration with Zymeworks

Tuesday, July 16, 2019 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Celgene Selects Lead Oncology Therapeutic Candidate Under Bispecific Antibody Collaboration with Zymeworks

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+23%
120-day peak, hindsight
Typical move
5.4%
average across 7 past catalysts
Cash runway
~35 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers

Full Press Release Details

Celgene Selects Lead Oncology Therapeutic Candidate Under Bispecific Antibody Collaboration with Zymeworks.
ShareAdd on Google
Tags: ZYME Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jul 16, 2019

Biotech snapshot

Cash runway
$374M liquidity · $11M/mo burn
~35 mo
Minimal dilution risk
Lead asset
ZW49Phase 1
HER2-expressing Cancers →

Catalyst track record

+23%
best trade around ZYME's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for ZYME.

See every catalyst's timing & PoA →